Abstract
Dendrobium officinale, an orchid of significant medicinal and ornamental value, exhibits poorly characterized hormonal regulation of flower bud differentiation. To address this knowledge gap, we employed an integrated multi-omics approach combining physiological, transcriptomic, metabolomic, and network analyses to elucidate the molecular mechanisms underlying the coordinated action of 6-Benzylaminopurine (6-BA) and Gibberellin A3 (GA(3)) in this critical developmental process. Our key findings reveal that combined 6-BA and GA(3) treatment significantly enhances flower bud differentiation and induces stage-specific fluctuations in soluble sugar, protein, and starch levels. Transcriptomic profiling identified 11,994 differentially expressed genes (DEGs), with DEGs specific to the hormone-treated stage showing pronounced enrichment in plant hormone signal transduction and plant-pathogen interaction pathways. Metabolomic analysis uncovered 18 stage-specific differential metabolites (DAMs) during hormone treatment, including GA(3), 6-BA, and OPDA, whose accumulation dynamics were strongly correlated with the progression of differentiation. Weighted gene co-expression network analysis (WGCNA) pinpointed key hub genes within the yellow module, notably transcription factors from the C2H2, bZIP, and NAC families. Their interaction network demonstrated significant correlation with the transcriptional regulation of hormone-responsive genes. Significantly, this study establishes the first molecular framework for 6-BA and GA(3) regulation of flower bud differentiation in D. officinale. We demonstrate a metabolomic-transcriptomic coordination network driven by these hormones, where key hub genes form regulatory modules with transcription factors. Dynamic shifts in endogenous hormones reinforce the flowering signal. These findings provide crucial molecular targets for precision flowering control and molecular breeding strategies in orchids.